Jane Street Group, LLC Innate Pharma Sa Transaction History

Jane Street Group, LLC

  • $445 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
BUY
$2.37 - $2.93 $34,492 - $42,643
14,554 New
14,554 $41,000
Q2 2022

Aug 16, 2022
SELL
$2.0 - $3.55 $75,472 - $133,962
-37,736 Closed
0 $0
Q1 2022

May 17, 2022
BUY
$2.7 - $4.8 $62,132 - $110,457
23,012 Added 156.29%
37,736 $127,000
Q4 2021

Feb 15, 2022
SELL
$4.34 - $6.06 $42,124 - $58,818
-9,706 Reduced 39.73%
14,724 $67,000
Q3 2021

Nov 16, 2021
BUY
$3.04 - $8.1 $74,267 - $197,883
24,430 New
24,430 $151,000

Others Institutions Holding IPHA

# of Institutions
9
Shares Held
238K
Call Options Held
0
Put Options Held
0
View Full List

About Innate Pharma SA

IPHA Quotes by TradingView
  • Ticker IPHA
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 79,893,000
  • Market Cap $141M
  • Description
  • Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and periphera...
More about IPHA
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email